INTRAOPERATIVE FLUORESCENCE-GUIDED RESECTION OF HIGH-GRADE GLYOBLASTOMA USING 5-AMINOLEVULINIC ACID: A META-ANALYSIS

Background. Glioblastoma (GBM) is a high-grade primary brain tumor characterized by resistance to modern treatment modalities. Intraoperative fluorescence-guided resection using 5-aminolevulinic acid (5-ALA) is one of the most innovative techniques to improve the local control rate in GBM surgery. Objective: to assess the diagnostic accuracy, sensitivity and specificity of 5-ALA fluorescence- guided resection (5-ALA-FGR) in patients with GBM. Material and methods. Surgical outcomes of 5-ALA-FGR in patients with GBM were studied in a meta-analysis of clinical series published from 2000 to 2017. Results. The meta-analysis included 26 studies. Gross total tumor resection was achieved in 74.8 % of patients (95 % CI: 67.4–83.5 %). The use of 5-ALA-FGR increased the disease-free survival time in patients with GBM by an average of 8.14 months (95 % CI: 4.36–12.02). The difference in the overall survival of GBM patients in favor of 5-ALA-FGR was 4.35–6.17 months (95 % CI: 0.9–13.23). The specificity and sensitivity of 5-ALA-FGR was high, being 86.6–87.5 % (95 % CI: 81.6–91.7) and 79.8–82.2 % (95 % CI: 73.5–91.07), respectively. Conclusion. The meta-analysis of 26 clinical series showed the high sensitivity and specificity of 5-ALA-FGR. Moreover, the use of 5-ALA-FGR in GBM was reported to increase the disease-free survival and the extent of surgical resection in patients with GBM.

1. Byvaltsev V.A., Stepanov I.A., Yarullina A.I., Belyh E.G. Molecular aspects of angiogenesis in gliobalstoma. Problems in Oncology. 2017; 63 (1): 19–27. [in Russian]

2. Belykh E., Martirosyan N.L., Yagmurlu K., Miller E.J., Eschbacher J.M., Izadyyazdanabadi M., Bardonova L.A., Byvaltsev V.A., Nakaji P., Preul M.C. Intraoperative Fluorescence Imaging for Personalized Brain Tumor Resection: Current State and Future Directions. Front Surg. 2016 Oct 17; 3: 55.

3. Golebiewska A., Bougnaud S., Stieber D., Brons N.H., Vallar L., Hertel F., Klink B., Schröck E., Bjerkvig R., Niclou S.P. Side population in human glioblastoma is non-tumorigenic and characterizes brain endothelial cells. Brain. 2013; 136 (5): 1462–1475.

4. Beier D., Schulz J.B., Beier C.P. Chemoresistance of glioblastoma cancer stem cells–much more complex than expected. Mol Cancer. 2011 Oct 11; 10: 128. doi: 10.1186/1476-4598-10-128.

5. Shirai K., Chakravarti A. Towards personalized therapy for patients with glioblastoma. Expert review of anticancer therapy. 2011; 11 (12): 1935–1944.

6. Raman F., Scribner E., Saut O., Wenger C., Colin T., Fathallah-Shaykh H.M. Computational Trials: Unraveling Motility Phenotypes, Progression Patterns, and Treatment Options for Glioblastoma Multiforme. Castro MG, ed. PLoS One. 2016 Jan 12; 11 (1): e0146617. doi: 10.1371/journal.pone.0146617.

7. Han K., Ren M., Wick W., Abrey L., Das A., Jin J., Reardon D.A. Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials. Neuro Oncol. 2014 May; 16 (5): 696–706. doi: 10.1093/neuonc/not236.

8. Byvaltsev V.A., Yarullina A.I., Stepanov I.A., Shashkov K.V. Glioblastoma resection with combined fluorescent navigation. Sib Med Journ. 2015; 138 (7): 128–132. [in Russian].

9. Teixidor P., Arráez M.Á., Villalba G., Garcia R., Tardáguila M., González J.J., Rimbau J., Vidal X., Montané E. Safety and Efficacy of 5-Aminolevulinic Acid for High Grade Glioma in Usual Clinical Practice: A Prospective Cohort Study. Black KL, ed. PLoS One. 2016 Feb 17; 11 (2): e0149244. doi: 10.1371/journal.pone.0149244.

10. Roberts D.W., Valdés P.A., Harris B.T., Hartov A., Fan X., Ji S., Leblond F., Tosteson T.D., Wilson B.C., Paulsen K.D. Glioblastoma Multiforme Treatment with Clinical Trials for Surgical Resection (Aminolevulinic Acid). Neurosurg Clin N Am. 2012 Jul; 23 (3): 371–7. doi: 10.1016/j.nec.2012.04.001

11. Piccirillo S.G., Dietz S., Madhu B., Griffiths J., Price S.J., Collins V.P., Watts C. Fluorescence-guided surgical sampling of glioblastoma identifies phenotypically distinct tumour-initiating cell populations in the tumour mass and margin. Br J Cancer. 2012 Jul 24; 107 (3): 462–8. doi: 10.1038/bjc.2012.271.

12. Chaichana K.L., Jusue-Torres I., Navarro-Ramirez R., Raza S.M., Pascual-Gallego M., Ibrahim A., Hernandez-Hermann M., Gomez L., Ye X., Weingart J.D., Olivi A., Blakeley J., Gallia G.L., Lim M., Brem H.,Quinones-Hinojosa. Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro Oncol. 2014 Jan; 16 (1): 113–22. doi: 10.1093/neuonc/not137.

13. Eljamel M.S. Brain photodiagnosis (PD), fluorescence guided resection (FGR) and photodynamic therapy (PDT): Past, present and future. Photodiagnosis Photodyn Ther. 2008 Mar; 5 (1): 29–35. doi: 10.1016/j.pdpdt.2008.01.006.

14. Kosinski A.S. A weighted generalized score statistic for comparison of predictive values of diagnostic tests. Stat Med. 2013 Mar 15; 32 (6): 964–77. doi: 10.1002/sim.5587.

15. Eljamel M.S., Goodman C., Moseley H. ALA and Photofrin fluorescence-guided resection and repetitive PDT in glioblastoma multiforme: A single centre Phase III randomised controlled trial. Lasers Medical Science. 2008; 23: 361–367.

16. Kalpathy-Cramer J., Gerstner E.R., Emblem K.E., Andronesi O., Rosen B. Advanced Magnetic Resonance Imaging of the Physical Processes in Human Glioblastoma. Cancer research. 2014; 74 (17): 4622–4637.

17. Stummer W., Novotny A., Stepp H., Goetz C., Bise K., Reulen H.J. Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: A prospective study in 52 consecutive patients. J Neurosurg. 2000; 93: 1003–1013.

18. Della Puppa A., Ciccarino P., Lombardi G., Rolma G., Cecchin D., Rossetto M. 5-Aminolevulinic acid fluorescence in high grade glioma surgery: Surgical outcome, intraoperative findings, and fluorescence patterns. Biomed Res Int. 2014; 2014: 232561. doi: 10.1155/2014/232561.

19. Piquer J., Llácer J.L., Rovira V., Riesgo P., Rodriguez R., Cremades A. Fluorescence-guided surgery and biopsy in gliomas with an exoscope system. Biomed Res Int. 2014; 2014: 207974. doi: 10.1155/2014/207974.

20. Stummer W., Pichlmeier U., Meinel T., Wiestler O.D., Zanella F., Reulen H.J.; ALA-Glioma Study Group. ALA-Glioma Study Group. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: A randomised controlled multicentre phase III trial. Lancet Oncol. 2008; 7: 392–401.

21. Della Puppa A., Lombardi G., Rossetto M., Rustemi O., Berti F., Cecchin D., Gardiman M.P., Rolma G., Persano L., Zagonel V., Scienza R. Outcome of patients affected by newly diagnosed glioblastoma undergoing surgery assisted by 5-aminolevulinic acid guided resection followed by BCNU wafers implantation: a 3-year follow-up. J Neurooncol. 2017 Jan; 131 (2): 331–340. doi: 10.1007/s11060-016-2301-z.

22. Pastor J., Vega-Zelaya L., Pulido P. Role of intraoperative neurophysiological monitoring during fluorescence-guided resection surgery. Acta Neurochir. 2013; 15: 2201–2213.

23. Díez Valle R., Slof J., Galván J., Arza C., Romariz C., Vidal C.; VISIONA study researchers. Observational, retrospective study of the effectiveness of 5-aminolevulinic acid in malignant glioma surgery in Spain (The VISIONA study). Neurologia. 2014 Apr; 29 (3): 131–8. doi: 10.1016/j.nrl.2013.05.004.

24. Della Puppa A., De Pellegrin S., d’Avella E., Gioffrè G., Rossetto M., Gerardi A., Lombardi G., Manara R., Munari M., Saladini M., Scienza R. 5-aminolevulinic acid (5-ALA) fluorescence guided surgery of high-grade gliomas in eloquent areas assisted by functional mapping. Our experience and review of the literature. Acta Neurochir (Wien). 2013 Jun; 155 (6): 965–72; discussion 972. doi: 10.1007/s00701-013-1660-x.

25. Jacquesson T., Ducray F., Maucort-Boulch D., Armoiry X., Louis-Tisserand G., Mbaye M., Pelissou-Guyotat I., Guyotat J. Surgery of high-grade gliomas guided by fluorescence: A retrospective study of 22 patients. Neurochirurgie. 2013 Feb; 59 (1): 9–16. doi: 10.1016/j.neuchi.2012.07.002

26. Díez Valle R., Tejada Solis S., Idoate Gastearena M.A., García de Eulate R., Domínguez Echávarri P., Aristu Mendiroz J. Surgery guided by 5-aminolevulinic fluorescence in glioblastoma: Volumetric analysis of extent of resection in single-center experience. J Neurooncol. 2011 Mar; 102 (1): 105–13. doi: 10.1007/s11060-010-0296-4.

27. Jaber M., Wölfer J., Ewelt C., Holling M., Hasselblatt M., Niederstadt T., Zoubi T., Weckesser M., Stummer W. The Value of 5-Aminolevulinic Acid in Low-grade Gliomas and High-grade Gliomas Lacking Glioblastoma Imaging Features: An Analysis Based on Fluorescence, Magnetic Resonance Imaging, 18F-Fluoroethyl Tyrosine Positron Emission Tomography, and Tumor Molecular Factors. Neurosurgery. 2016 Mar; 78 (3): 401–11; discussion 411. doi: 10.1227/NEU.0000000000001020.

28. Slotty P.J., Siantidis B., Beez T., Steiger H.J., Sabel M. The impact of improved treatment strategies on overall survival in glioblastoma patients. Acta Neurochir (Wien). 2013 Jun; 155 (6): 959–63. doi: 10.1007/s00701-013-1693-1.

29. Hefti M., von Campe G., Moschopulos M., Siegner A., Looser H., Landolt H. 5-aminolevulinic acid induced protoporphyrin IX fluorescence in high-grade glioma surgery: A one-year experience at a single institutuion. Swiss Med Wkly. 2008 Mar 22; 138 (11–12): 180–5. doi: 2008/11/smw-12077.

30. Valdés P.A., Kim A., Leblond F., Conde O.M., Harris B.T., Paulsen K.D., Wilson B.C., Roberts D.W. Combined fluorescence and reflectance spectroscopy for in vivo quantification of cancer biomarkers in low- and high-grade glioma surgery. J Biomed Opt. 2011 Nov; 16 (11): 116007. doi: 10.1117/1.3646916.

31. Ewelt C., Floeth F.W., Felsberg J., Steiger H.J., Sabel M., Langen K.J., Stoffels G., Stummer W. Finding the anaplastic focus in diffuse gliomas: The value of Gd-DTPA enhance MRI, FET-PET, and intraoperative, ALA-derived tissue fluorescence. Clin Neurol Neurosurg. 2011 Sep; 113 (7): 541–7. doi: 10.1016/j.clineuro.2011.03.008.

32. Kremer P., Fardanesh M., Ding R., Pritsch M., Zoubaa S., Frei E. Intraoperative fluorescence staining of malignant brain tumors using 5-aminofluorescein-labeled albumin. Neurosurgery. 2009 Mar; 64 (3 Suppl): ons53–60. doi: 10.1227/01.NEU.0000335787.17029.67.

33. Floeth F.W., Sabel M., Ewelt C., Stummer W., Felsberg J., Reifenberger G., Steiger H.J., Stoffels G., Coenen H.H., Langen K.J. Comparison of 18F-FET PET and 5-ALA fluorescence in cerebral gliomas. Eur J Nucl Med Mol Imaging. 2011 Apr; 38 (4): 731–41. doi: 10.1007/s00259-010-1690-z.

34. Panciani P.P., Fontanella M., Schatlo B., Garbossa D., Agnoletti A., Ducati A., Lanotte M. Fluorescence and image guided resection in high grade glioma. Clin Neurol Neurosurg. 2012 Jan; 114 (1): 37–41. doi: 10.1016/j.clineuro.2011.09.001.

35. Su X., Huang Q.F., Chen H.L., Chen J. Fluorescence-guided resection of high-grade gliomas: A systematic review and meta-analysis. Photodiagnosis Photodyn Ther. 2014 Dec; 11 (4): 451–8. doi: 10.1016/j.pdpdt.2014.08.001.

36. Zhao S., Wu J., Wang C., Liu H., Dong X., Shi C., Shi C., Liu Y., Teng L., Han D., Chen X., Yang G., Wang L., Shen C., Li H. Intraoperative Fluorescence-Guided Resection of High-Grade Malignant Gliomas Using 5-Aminolevulinic Acid–Induced Porphyrins: A Systematic Review and Meta-Analysis of Prospective Studies. PLoS One. 2013 May 28; 8 (5):e63682. doi: 10.1371/journal.pone.0063682.

37. Eljamel S. 5-ALA Fluorescence Image Guided Resection of Glioblastoma Multiforme: A Meta-Analysis of the Literature. Hamblin MR, ed. International J Mol Sci. 2015; 16 (5): 10443–10456.